Cours suspendu

Communiqués Durect

Actions

DRRX

US2666055007

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/09/2025			Varia. 5j.	Varia. 1 janv.
1,910 ^USD	-1,04%		-.--%	-

11/09/25	Bausch Health finalise l'acquisition de DURECT Corporation	CI
11/09/25	Bausch Health finalise l'acquisition de Durect pour 63 millions de dollars et intègre une thérapie innovante contre l'hépatite à son portefeuille	MT

Communiqués

12/08/25	Durect: Q2 Earnings Snapshot	AQ
12/08/25	DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health	PR
15/05/25	Durect: Q1 Earnings Snapshot	AQ
13/05/25	DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update	PR
26/03/25	Durect: Q4 Earnings Snapshot	AQ
19/03/25	DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update	PR
04/02/25	DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference	PR
28/01/25	DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence	PR
29/11/24	DURECT : Amendment to Current Report Form 8 K/A	PU
26/11/24	DURECT Corporation Announces Sale of ALZET Product Line to Lafayette Instrument Co. for $17.5 Million	AQ
25/11/24	DURECT : Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million Form 8 K	PU
13/11/24	DURECT : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	PU
13/11/24	Durect: Q3 Earnings Snapshot	AQ
06/11/24	DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update	PR
25/09/24	DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis	PR
04/09/24	DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference	PR
13/08/24	Durect: Q2 Earnings Snapshot	AQ
13/08/24	DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update	PR
07/08/24	DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update	PR
21/05/24	DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	PR
13/05/24	Durect: Q1 Earnings Snapshot	AQ
13/05/24	DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update	PR
07/05/24	DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update	PR
30/04/24	DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis	PR
27/03/24	Durect: Q4 Earnings Snapshot	AQ